第十一批药品集采正式报量，“反内卷”再获强调，医疗器械指数ETF（159898）早盘直线拉涨近2.5%

Group 1 - The core viewpoint of the news is that the medical device sector in A-shares has become a leading performer following the initiation of the 11th batch of national drug procurement, with the medical device index rising by 2.37% [1] - The 11th batch of national drug procurement involves 55 mature products and emphasizes the principle of "anti-involution," encouraging companies to conduct rational pricing and resist illegal practices [1][2] - The medical device index ETF (159898) has seen significant capital inflow, with a net inflow of 38.59 million yuan over the past 10 days and 54.37 million yuan over the past 20 days [2] Group 2 - Notable stock performances include SINO Medical hitting the daily limit up by 20%, while several other companies like Berry Genomics and Kehua Bio also saw significant gains [2] - Since the low point on June 19, the medical device index has rebounded by 11.35%, outperforming the Shanghai and Shenzhen 300 index, which increased by 6.36% during the same period [2] - Analysts from CITIC Securities suggest that the recent emphasis on "anti-involution" and the optimization of procurement policies signal a turning point for the medical device sector, with potential for valuation and performance recovery [2][3] Group 3 - The A-share medical device index has experienced a continuous decline over the past four years due to policy factors such as procurement and compliance requirements, but has started to rebound since early 2025 [3] - With the easing of policies and the clearing of procurement processes, many companies are expected to see performance and valuation recovery, with high growth anticipated in the second half of 2025 and 2026 [3]